+ND Capital

AIRNA is a biotech company that is pioneering RNA editing therapies to improve the health of individuals suffering from both rare and common ailments.

Constructive Bio is a biotechnology company focused on genome rewriting to unlock new possibilities in bioprocesses and biopharmaceuticals. The company transforms living cells into biofactories, producing sustainable materials and therapeutics. By harnessing advanced technologies, Constructive Bio creates virus-resistant organisms and biosynthesizes a range of enzymes, pharmaceuticals, and biomaterials. This innovative approach allows clients to reprogram genetic codes, enabling the creation of natural molecules that were previously inaccessible through conventional biology. Through its unique capabilities, Constructive Bio aims to lead the development of the next generation of sustainable solutions in the life sciences.

Vandria is a biotechnology company focused on developing mitophagy inducers that promote cellular renewal to combat aging and chronic diseases. These inducers target the elimination and recycling of damaged mitochondria through the autophagy process, which is essential for maintaining healthy mitochondrial function. By enhancing this cellular mechanism, Vandria aims to help patients prevent age-related disorders and improve overall health.

AIRNA is a biotech company that is pioneering RNA editing therapies to improve the health of individuals suffering from both rare and common ailments.

PulseSight Therapeutics is an ophthalmology-focused company dedicated to developing innovative, non-viral gene therapies aimed at treating severe retinal diseases that can lead to blindness. The company specializes in therapeutic proteins designed to address a range of conditions, including chronic non-infectious uveitis, degenerative diseases, retinal vascular diseases, and macular edema. By employing minimally invasive delivery technologies, PulseSight enhances compliance, ocular bioavailability, and tolerability, thereby enabling healthcare providers to improve the quality of life and preserve vision for their patients.

Vandria is a biotechnology company focused on developing mitophagy inducers that promote cellular renewal to combat aging and chronic diseases. These inducers target the elimination and recycling of damaged mitochondria through the autophagy process, which is essential for maintaining healthy mitochondrial function. By enhancing this cellular mechanism, Vandria aims to help patients prevent age-related disorders and improve overall health.

Partillion Bioscience is an early-stage life science company focused on developing a functional single-cell analysis platform. This innovative platform utilizes a novel nano vial technology to rapidly compartmentalize and analyze millions of single cells, specifically targeting secreted proteins. By enabling detailed examination of biological functions, Partillion aims to democratize advanced single-cell assays for biotech laboratories and clients. This capability supports the development of more effective therapies for various conditions, including cancer, autoimmune diseases, and infectious diseases.

Notify Therapeutics is focused on developing innovative therapies for the treatment of infertility, specifically targeting women who do not respond to standard hormone therapy. The company’s approach centers on the early and hormone-independent phase of egg maturation, utilizing drug-inducing factors that regulate the intracellular AKT pathway. This unique methodology aims to enhance ovarian follicle development in women with low ovarian reserves, thereby improving their chances of successful conception. By providing a non-hormonal alternative, Notify Therapeutics seeks to address the needs of infertile women while minimizing the risks associated with multiple pregnancies.

H55 S.A., founded in 2015 and based in Sion, Switzerland, specializes in manufacturing electric propulsion systems and battery management solutions for aircraft. The company develops certified technology aimed at transforming aviation into a clean, quiet, and efficient mode of transportation. Its offerings include both software and hardware solutions that integrate various components such as propellers, transmission systems, electric motors, controllers, and energy storage systems. Additionally, H55 focuses on creating effective pilot interfaces and control systems, contributing to the advancement of autonomous aviation. Through its innovations, H55 is committed to facilitating a revolution in air transportation that prioritizes sustainability and efficiency.

AIRNA is a biotech company that is pioneering RNA editing therapies to improve the health of individuals suffering from both rare and common ailments.

Lightcast Discovery Limited, founded in 2019 and based in Cambridge, United Kingdom, specializes in advancing drug discovery through its innovative microfluidic platform. This technology allows for precise control of thousands of droplets, enabling complex cell analysis and workflows without manual manipulation. By leveraging this platform, Lightcast collaborates with major pharmaceutical companies and leading academic institutions to develop new therapies and products. The company's focus is on pushing the boundaries of complex cell analysis, thereby facilitating the discovery of unique clinical approaches in the field of drug development.

SPARK Microsystems is a fabless semiconductor company focused on advancing ultra-low power wireless communications for the Internet of Things. The company has developed a high-performance wireless transceiver that significantly improves energy efficiency, reduces latency, and enhances data rates compared to existing technologies. By utilizing its patented technology, SPARK Microsystems enables the extended battery life of electronic devices, allowing clients to implement battery-less wireless operations and enhance overall efficiency. This innovation positions SPARK Microsystems as a leader in the evolving landscape of IoT communication solutions.

Natron Energy, Inc. is an energy storage company based in Santa Clara, California, founded in 2012. The company specializes in developing sodium-ion battery technologies, utilizing Prussian Blue electrode materials to create safe and sustainable energy storage solutions. Natron's batteries are designed for various industrial applications, including uninterruptible power supply systems, lift trucks, renewable energy smoothing, and smart grids. These batteries offer advantages such as high power density, efficient recharging, and extended cycle life, and can be produced economically using commodity materials on existing manufacturing lines. Natron Energy operates a software-defined power platform to enhance the integration of its battery solutions across critical backup power systems and other applications.

SiMa.ai is a company based in San Jose, California, focused on designing and developing a machine learning platform that provides a single-chip solution for embedded systems. The company specializes in machine learning system-on-chip (MLSoC) technology, which allows for high-performance machine learning inference at low power in edge applications. SiMa.ai's platform enables seamless deployment and scaling of machine learning solutions, addressing various computer vision challenges with significantly improved performance and energy efficiency. The hardware-to-software stack of SiMa.ai is adaptable to multiple frameworks and models, enhancing the capabilities of applications in areas such as computer vision and generative AI. Founded in 2018, SiMa.ai aims to facilitate the integration of advanced machine learning technology into embedded systems while ensuring safe and secure operations.

Favik is an online platform established in 2020 and based in Bogotá, Colombia, that supports influencers in building and managing their brands. The company offers comprehensive brand creation software that assists creators and influencers in various aspects of their business, including marketing, retail, technology, operations, finance, and overall business strategy. This enables social influencers and content creators to develop their brands while managing all operational tasks, from product production to consumer delivery.

SiMa.ai is a company based in San Jose, California, focused on designing and developing a machine learning platform that provides a single-chip solution for embedded systems. The company specializes in machine learning system-on-chip (MLSoC) technology, which allows for high-performance machine learning inference at low power in edge applications. SiMa.ai's platform enables seamless deployment and scaling of machine learning solutions, addressing various computer vision challenges with significantly improved performance and energy efficiency. The hardware-to-software stack of SiMa.ai is adaptable to multiple frameworks and models, enhancing the capabilities of applications in areas such as computer vision and generative AI. Founded in 2018, SiMa.ai aims to facilitate the integration of advanced machine learning technology into embedded systems while ensuring safe and secure operations.

CytoKi Pharma ApS is a discovery-stage biotechnology company based in Værløse, Denmark, founded in 2019. The company focuses on developing innovative treatments for diseases with significant unmet medical needs, particularly those resulting from epithelial injury. CytoKi Pharma is currently in the pre-clinical stage and is advancing its lead program, which involves an engineered long-acting IL-22 protein licensed from a major pharmaceutical entity. IL-22 is a crucial cytokine that plays a vital role in the immune system's response to tissue injury, acting as a signal for survival and recovery. By harnessing the therapeutic potential of this modified IL-22 protein, CytoKi Pharma aims to address the challenges posed by organ injuries and improve patient outcomes in affected populations.

Icosavax, Inc. is a biotechnology company based in Seattle, Washington, founded in 2017. The company specializes in developing vaccines using its innovative virus-like particle (VLP) technology platform, which allows for the multivalent display of complex viral antigens. This technology aims to provide broad and durable protection against various infectious diseases, with an initial focus on life-threatening respiratory illnesses. Icosavax's pipeline includes vaccine candidates targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and SARS-CoV-2. The company is dedicated to advancing its VLP technology to discover, develop, and ultimately commercialize effective vaccines against these infectious diseases.

H55 S.A., founded in 2015 and based in Sion, Switzerland, specializes in manufacturing electric propulsion systems and battery management solutions for aircraft. The company develops certified technology aimed at transforming aviation into a clean, quiet, and efficient mode of transportation. Its offerings include both software and hardware solutions that integrate various components such as propellers, transmission systems, electric motors, controllers, and energy storage systems. Additionally, H55 focuses on creating effective pilot interfaces and control systems, contributing to the advancement of autonomous aviation. Through its innovations, H55 is committed to facilitating a revolution in air transportation that prioritizes sustainability and efficiency.

Natron Energy, Inc. is an energy storage company based in Santa Clara, California, founded in 2012. The company specializes in developing sodium-ion battery technologies, utilizing Prussian Blue electrode materials to create safe and sustainable energy storage solutions. Natron's batteries are designed for various industrial applications, including uninterruptible power supply systems, lift trucks, renewable energy smoothing, and smart grids. These batteries offer advantages such as high power density, efficient recharging, and extended cycle life, and can be produced economically using commodity materials on existing manufacturing lines. Natron Energy operates a software-defined power platform to enhance the integration of its battery solutions across critical backup power systems and other applications.

Orca Bio is a clinical-stage cell therapy company focused on providing curative treatments for patients suffering from malignant and autoimmune diseases. The company has developed proprietary technologies aimed at replacing diseased blood and immune systems with healthy cells. Orca Bio specializes in the research and development of innovative cell therapies that enhance the effectiveness of bone marrow transplants, creating a life-saving platform for various medical conditions. With a team of leading experts and technologists, Orca Bio is committed to advancing its pipeline of therapies to improve patient outcomes and transform healthcare practices.

SQZ Biotech is a clinical-stage biotechnology company focused on developing innovative cell therapies for patients facing cancer, infectious diseases, and other serious health conditions. Utilizing its proprietary CellSqueeze technology, SQZ Biotech can deliver a variety of materials into diverse patient cell types, enabling the engineering of therapies that address a wide array of clinical challenges. The company aims to create well-tolerated cell therapies that not only enhance therapeutic benefits but also improve the overall patient experience compared to traditional cell therapy methods. Through a combination of internal research initiatives and external collaborations, SQZ Biotech is advancing a new generation of cellular therapies aimed at both immune activation and immune suppression.

SiMa.ai is a company based in San Jose, California, focused on designing and developing a machine learning platform that provides a single-chip solution for embedded systems. The company specializes in machine learning system-on-chip (MLSoC) technology, which allows for high-performance machine learning inference at low power in edge applications. SiMa.ai's platform enables seamless deployment and scaling of machine learning solutions, addressing various computer vision challenges with significantly improved performance and energy efficiency. The hardware-to-software stack of SiMa.ai is adaptable to multiple frameworks and models, enhancing the capabilities of applications in areas such as computer vision and generative AI. Founded in 2018, SiMa.ai aims to facilitate the integration of advanced machine learning technology into embedded systems while ensuring safe and secure operations.

Arctos Medical is a spin-off from the University of Bern that focuses on developing optogenetic therapies to address common forms of blindness, particularly those caused by inherited retinal dystrophies (IRDs). Unlike traditional approaches that target rare genetic eye diseases, Arctos Medical's innovative gene therapy aims to enhance the quality of visual information transmitted to the brain, thereby offering potential treatments for patients experiencing complete vision loss. Through its research and development efforts, the company seeks to improve the lives of individuals affected by various forms of blindness.

Icosavax, Inc. is a biotechnology company based in Seattle, Washington, founded in 2017. The company specializes in developing vaccines using its innovative virus-like particle (VLP) technology platform, which allows for the multivalent display of complex viral antigens. This technology aims to provide broad and durable protection against various infectious diseases, with an initial focus on life-threatening respiratory illnesses. Icosavax's pipeline includes vaccine candidates targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and SARS-CoV-2. The company is dedicated to advancing its VLP technology to discover, develop, and ultimately commercialize effective vaccines against these infectious diseases.

Amphivena Therapeutics is a clinical-stage immuno-oncology company focused on developing bifunctional antibody therapies aimed at treating hematologic malignancies. Founded in 2012 and based in South San Francisco, California, the company utilizes its proprietary ReSTORE platform to create dual-action biologics that enhance the patient's immune response against cancer. These therapies are designed to relieve immune suppression while activating T cells, thereby promoting the destruction of tumor cells and their precursors. The platform emphasizes avidity, target selectivity, and safety, and can be engineered to include additional functionalities for targeting solid tumors. As a subsidiary of Affimed N.V., Amphivena Therapeutics aims to provide innovative treatment options for patients facing blood cancers.

Inscripta, Inc. is a gene editing technology company based in Boulder, Colorado, with additional offices in Pleasanton and San Diego, California. Founded in 2015, Inscripta focuses on developing CRISPR enzymes, specifically MADzymes, for precision gene editing. The company has created a benchtop platform for scalable digital genome engineering, which includes an instrument, consumables, software, and assays that facilitate a fully automated workflow. This platform allows for massively parallel and trackable editing of single cells, significantly enhancing the scale and efficiency of gene editing research. By making its MAD7 CRISPR nuclease freely available for research and development, Inscripta aims to remove existing technical and licensing barriers, thereby empowering scientists and fostering a new era of biological discovery.

Inscripta, Inc. is a gene editing technology company based in Boulder, Colorado, with additional offices in Pleasanton and San Diego, California. Founded in 2015, Inscripta focuses on developing CRISPR enzymes, specifically MADzymes, for precision gene editing. The company has created a benchtop platform for scalable digital genome engineering, which includes an instrument, consumables, software, and assays that facilitate a fully automated workflow. This platform allows for massively parallel and trackable editing of single cells, significantly enhancing the scale and efficiency of gene editing research. By making its MAD7 CRISPR nuclease freely available for research and development, Inscripta aims to remove existing technical and licensing barriers, thereby empowering scientists and fostering a new era of biological discovery.

SQZ Biotech is a clinical-stage biotechnology company focused on developing innovative cell therapies for patients facing cancer, infectious diseases, and other serious health conditions. Utilizing its proprietary CellSqueeze technology, SQZ Biotech can deliver a variety of materials into diverse patient cell types, enabling the engineering of therapies that address a wide array of clinical challenges. The company aims to create well-tolerated cell therapies that not only enhance therapeutic benefits but also improve the overall patient experience compared to traditional cell therapy methods. Through a combination of internal research initiatives and external collaborations, SQZ Biotech is advancing a new generation of cellular therapies aimed at both immune activation and immune suppression.

Serotiny, Inc. is a biotechnology company based in San Francisco that specializes in the design and development of multi-domain proteins and therapies for cancer and genetic disorders. Founded in 2014, the company leverages a combination of synthetic biology and advanced informatics to create innovative therapeutic proteins, particularly for CAR T-cell therapies. Its platform integrates computational protein design, high-throughput cellular assays, and next-generation sequencing to engineer complex proteins effectively. By applying expertise from various fields such as immunology, machine learning, and bioinformatics, Serotiny aims to enhance the safety and efficacy of gene and cell therapies through novel control methods and engineered functionalities.

Inscripta, Inc. is a gene editing technology company based in Boulder, Colorado, with additional offices in Pleasanton and San Diego, California. Founded in 2015, Inscripta focuses on developing CRISPR enzymes, specifically MADzymes, for precision gene editing. The company has created a benchtop platform for scalable digital genome engineering, which includes an instrument, consumables, software, and assays that facilitate a fully automated workflow. This platform allows for massively parallel and trackable editing of single cells, significantly enhancing the scale and efficiency of gene editing research. By making its MAD7 CRISPR nuclease freely available for research and development, Inscripta aims to remove existing technical and licensing barriers, thereby empowering scientists and fostering a new era of biological discovery.

H55 S.A., founded in 2015 and based in Sion, Switzerland, specializes in manufacturing electric propulsion systems and battery management solutions for aircraft. The company develops certified technology aimed at transforming aviation into a clean, quiet, and efficient mode of transportation. Its offerings include both software and hardware solutions that integrate various components such as propellers, transmission systems, electric motors, controllers, and energy storage systems. Additionally, H55 focuses on creating effective pilot interfaces and control systems, contributing to the advancement of autonomous aviation. Through its innovations, H55 is committed to facilitating a revolution in air transportation that prioritizes sustainability and efficiency.

ARMO BioSciences, Inc. is an immuno-oncology company based in Redwood City, California, focused on developing biologic therapeutics that stimulate the immune system to combat cancer. The company's product pipeline includes several innovative candidates, such as AM0010, a long-acting form of interleukin-10 that enhances immune response, and AM0001, an anti-PD-1 monoclonal antibody targeting various cancers. Other key products in development include an anti-LAG-3 checkpoint inhibitor, AM0015, a recombinant form of interleukin-15, and AM0012, a recombinant interleukin-12. Established in 2010 and formerly known as Targenics, ARMO BioSciences aims to activate and enhance the body's immune response against tumors, thereby improving outcomes for cancer patients. As of mid-2018, it operates as a subsidiary of Eli Lilly and Company.

Inscripta, Inc. is a gene editing technology company based in Boulder, Colorado, with additional offices in Pleasanton and San Diego, California. Founded in 2015, Inscripta focuses on developing CRISPR enzymes, specifically MADzymes, for precision gene editing. The company has created a benchtop platform for scalable digital genome engineering, which includes an instrument, consumables, software, and assays that facilitate a fully automated workflow. This platform allows for massively parallel and trackable editing of single cells, significantly enhancing the scale and efficiency of gene editing research. By making its MAD7 CRISPR nuclease freely available for research and development, Inscripta aims to remove existing technical and licensing barriers, thereby empowering scientists and fostering a new era of biological discovery.

Tarveda Therapeutics is focused on developing innovative cancer therapies specifically for solid tumors. The company specializes in miniature drug conjugates, with its lead candidate, PEN-866, targeting activated Heat Shock Protein 90 (HSP90) to deliver a potent topoisomerase 1 inhibitor, SN38, directly to tumor cells. Additionally, Tarveda is advancing another drug conjugate aimed at treating patients with neuroendocrine tumors and small cell lung cancer that express somatostatin receptor 2 (SSTR2). By leveraging its targeted drug delivery platform, Tarveda Therapeutics aims to improve treatment outcomes for patients with difficult-to-treat cancers while reducing potential side effects. Founded in 2011 and based in Watertown, Massachusetts, the company was previously known as Blend Therapeutics until its rebranding in 2016.

Emulate, Inc. specializes in organ-on-chip technology that simulates human biology to enhance the understanding of how diseases, medications, chemicals, and food impact human health. The company develops organ-chips for various organs, including the lung, intestine, liver, and skin, which replicate normal functions and disease conditions. Emulate's innovative technology offers researchers a more accurate alternative to traditional experimental methods, such as cell cultures and animal testing, by providing detailed insights into human biological responses. Additionally, the company supplies drug development and instrumentation software to facilitate research and development workflows for its clients. Emulate serves a diverse range of sectors, including biotechnology, pharmaceuticals, consumer health, cosmetics, chemicals, food, agrochemicals, government agencies, and academic institutions. Founded in 2013 and headquartered in Boston, Massachusetts, Emulate was previously known as Emulate Living MicroDevices, Inc. until its name change in 2014.

SQZ Biotech is a clinical-stage biotechnology company focused on developing innovative cell therapies for patients facing cancer, infectious diseases, and other serious health conditions. Utilizing its proprietary CellSqueeze technology, SQZ Biotech can deliver a variety of materials into diverse patient cell types, enabling the engineering of therapies that address a wide array of clinical challenges. The company aims to create well-tolerated cell therapies that not only enhance therapeutic benefits but also improve the overall patient experience compared to traditional cell therapy methods. Through a combination of internal research initiatives and external collaborations, SQZ Biotech is advancing a new generation of cellular therapies aimed at both immune activation and immune suppression.

ARMO BioSciences, Inc. is an immuno-oncology company based in Redwood City, California, focused on developing biologic therapeutics that stimulate the immune system to combat cancer. The company's product pipeline includes several innovative candidates, such as AM0010, a long-acting form of interleukin-10 that enhances immune response, and AM0001, an anti-PD-1 monoclonal antibody targeting various cancers. Other key products in development include an anti-LAG-3 checkpoint inhibitor, AM0015, a recombinant form of interleukin-15, and AM0012, a recombinant interleukin-12. Established in 2010 and formerly known as Targenics, ARMO BioSciences aims to activate and enhance the body's immune response against tumors, thereby improving outcomes for cancer patients. As of mid-2018, it operates as a subsidiary of Eli Lilly and Company.

Euphrates Vascular is a medical technology company based in St. Louis, Missouri, that focuses on innovative solutions for the treatment of stroke, heart disease, and other conditions. The company has developed a proprietary magnetically-enhanced diffusion (MED) system that utilizes magnet-based technology to dissolve blood clots more rapidly than existing treatment options. This system aims to improve the efficacy of FDA-approved clot-busting medications, potentially reducing mortality rates associated with stroke and cardiovascular diseases. In addition to the MED system, Euphrates Vascular offers MED MicroBeads, which are designed to deliver therapeutic agents directly to clots during thrombolysis therapy, and a touch screen-operated MED Workstation. Founded by physicists with extensive experience in medical technology, the company continues to advance its pioneering approaches in the healthcare sector, attracting interest from investors and media alike.

Twist Bioscience Corporation is a synthetic biology company that specializes in the manufacture and sale of synthetic DNA-based products. Founded in 2013 and headquartered in South San Francisco, California, the company utilizes a proprietary semiconductor-based DNA synthesis platform that writes DNA on silicon chips, allowing for the rapid and cost-effective production of high-quality synthetic DNA. Twist Bioscience's offerings include synthetic genes, tools for sample preparation, antibody libraries for drug discovery, and DNA as a medium for digital data storage. The company serves various sectors, including healthcare, agriculture, and industrial chemicals, supporting customers in their efforts to enhance lives and promote sustainability. Through its innovative platform, Twist Bioscience aims to overcome traditional inefficiencies in DNA synthesis, enabling researchers to accelerate their projects.

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary platform utilizes advances in immunobiology and nanotechnology to create targeted immunomodulatory nanoparticles. Selecta's lead product, SEL-212, has successfully completed Phase II clinical trials for chronic refractory gout. Additionally, the company is advancing gene therapy candidates in preclinical development for rare metabolic disorders, including SEL-302 for methylmalonic acidemia and SEL-313 for ornithine transcarbamylase deficiency. Founded in 2007 and headquartered in Watertown, Massachusetts, Selecta Biosciences has established collaborations with various organizations, including Spark Therapeutics and the Massachusetts Institute of Technology, to enhance its research and development capabilities.

Crocus Technology SA specializes in magnetic random access memory products and technologies tailored for the semiconductor and electronic systems industries. The company develops magnetic sensors and embedded memory technology that facilitate efficient sensor data gathering and processing. Its products are designed for diverse applications, including telecommunications, networking, storage, computing, and handheld devices. Crocus Technology's innovative solutions enable fast read and write operations while maintaining a compact footprint, which enhances chip performance and security for devices such as smart cards, mobile phones, and data servers. By focusing on high sensitivity, stable temperature performance, and low power consumption, the company aims to improve productivity for its clients across various sectors.

Twist Bioscience Corporation is a synthetic biology company that specializes in the manufacture and sale of synthetic DNA-based products. Founded in 2013 and headquartered in South San Francisco, California, the company utilizes a proprietary semiconductor-based DNA synthesis platform that writes DNA on silicon chips, allowing for the rapid and cost-effective production of high-quality synthetic DNA. Twist Bioscience's offerings include synthetic genes, tools for sample preparation, antibody libraries for drug discovery, and DNA as a medium for digital data storage. The company serves various sectors, including healthcare, agriculture, and industrial chemicals, supporting customers in their efforts to enhance lives and promote sustainability. Through its innovative platform, Twist Bioscience aims to overcome traditional inefficiencies in DNA synthesis, enabling researchers to accelerate their projects.

Tarveda Therapeutics is focused on developing innovative cancer therapies specifically for solid tumors. The company specializes in miniature drug conjugates, with its lead candidate, PEN-866, targeting activated Heat Shock Protein 90 (HSP90) to deliver a potent topoisomerase 1 inhibitor, SN38, directly to tumor cells. Additionally, Tarveda is advancing another drug conjugate aimed at treating patients with neuroendocrine tumors and small cell lung cancer that express somatostatin receptor 2 (SSTR2). By leveraging its targeted drug delivery platform, Tarveda Therapeutics aims to improve treatment outcomes for patients with difficult-to-treat cancers while reducing potential side effects. Founded in 2011 and based in Watertown, Massachusetts, the company was previously known as Blend Therapeutics until its rebranding in 2016.

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary platform utilizes advances in immunobiology and nanotechnology to create targeted immunomodulatory nanoparticles. Selecta's lead product, SEL-212, has successfully completed Phase II clinical trials for chronic refractory gout. Additionally, the company is advancing gene therapy candidates in preclinical development for rare metabolic disorders, including SEL-302 for methylmalonic acidemia and SEL-313 for ornithine transcarbamylase deficiency. Founded in 2007 and headquartered in Watertown, Massachusetts, Selecta Biosciences has established collaborations with various organizations, including Spark Therapeutics and the Massachusetts Institute of Technology, to enhance its research and development capabilities.

Emulate, Inc. specializes in organ-on-chip technology that simulates human biology to enhance the understanding of how diseases, medications, chemicals, and food impact human health. The company develops organ-chips for various organs, including the lung, intestine, liver, and skin, which replicate normal functions and disease conditions. Emulate's innovative technology offers researchers a more accurate alternative to traditional experimental methods, such as cell cultures and animal testing, by providing detailed insights into human biological responses. Additionally, the company supplies drug development and instrumentation software to facilitate research and development workflows for its clients. Emulate serves a diverse range of sectors, including biotechnology, pharmaceuticals, consumer health, cosmetics, chemicals, food, agrochemicals, government agencies, and academic institutions. Founded in 2013 and headquartered in Boston, Massachusetts, Emulate was previously known as Emulate Living MicroDevices, Inc. until its name change in 2014.

ARMO BioSciences, Inc. is an immuno-oncology company based in Redwood City, California, focused on developing biologic therapeutics that stimulate the immune system to combat cancer. The company's product pipeline includes several innovative candidates, such as AM0010, a long-acting form of interleukin-10 that enhances immune response, and AM0001, an anti-PD-1 monoclonal antibody targeting various cancers. Other key products in development include an anti-LAG-3 checkpoint inhibitor, AM0015, a recombinant form of interleukin-15, and AM0012, a recombinant interleukin-12. Established in 2010 and formerly known as Targenics, ARMO BioSciences aims to activate and enhance the body's immune response against tumors, thereby improving outcomes for cancer patients. As of mid-2018, it operates as a subsidiary of Eli Lilly and Company.

Twist Bioscience Corporation is a synthetic biology company that specializes in the manufacture and sale of synthetic DNA-based products. Founded in 2013 and headquartered in South San Francisco, California, the company utilizes a proprietary semiconductor-based DNA synthesis platform that writes DNA on silicon chips, allowing for the rapid and cost-effective production of high-quality synthetic DNA. Twist Bioscience's offerings include synthetic genes, tools for sample preparation, antibody libraries for drug discovery, and DNA as a medium for digital data storage. The company serves various sectors, including healthcare, agriculture, and industrial chemicals, supporting customers in their efforts to enhance lives and promote sustainability. Through its innovative platform, Twist Bioscience aims to overcome traditional inefficiencies in DNA synthesis, enabling researchers to accelerate their projects.

Tarveda Therapeutics is focused on developing innovative cancer therapies specifically for solid tumors. The company specializes in miniature drug conjugates, with its lead candidate, PEN-866, targeting activated Heat Shock Protein 90 (HSP90) to deliver a potent topoisomerase 1 inhibitor, SN38, directly to tumor cells. Additionally, Tarveda is advancing another drug conjugate aimed at treating patients with neuroendocrine tumors and small cell lung cancer that express somatostatin receptor 2 (SSTR2). By leveraging its targeted drug delivery platform, Tarveda Therapeutics aims to improve treatment outcomes for patients with difficult-to-treat cancers while reducing potential side effects. Founded in 2011 and based in Watertown, Massachusetts, the company was previously known as Blend Therapeutics until its rebranding in 2016.

View is a technology company specializing in smart building solutions, particularly through its innovative smart windows. These windows utilize artificial intelligence to automatically adjust to sunlight, enhancing natural light access and providing unobstructed views while also minimizing heat and glare. This technology not only improves the health and overall experience of occupants but also reduces energy consumption and carbon emissions. View's products are integrated into a cloud-connected smart building platform, which includes essential infrastructure for power, networking, and communication. The company has successfully implemented its solutions in over 90 million square feet of various building types, including offices, hospitals, airports, educational institutions, hotels, and multifamily residences.

Crocus Technology SA specializes in magnetic random access memory products and technologies tailored for the semiconductor and electronic systems industries. The company develops magnetic sensors and embedded memory technology that facilitate efficient sensor data gathering and processing. Its products are designed for diverse applications, including telecommunications, networking, storage, computing, and handheld devices. Crocus Technology's innovative solutions enable fast read and write operations while maintaining a compact footprint, which enhances chip performance and security for devices such as smart cards, mobile phones, and data servers. By focusing on high sensitivity, stable temperature performance, and low power consumption, the company aims to improve productivity for its clients across various sectors.

View is a technology company specializing in smart building solutions, particularly through its innovative smart windows. These windows utilize artificial intelligence to automatically adjust to sunlight, enhancing natural light access and providing unobstructed views while also minimizing heat and glare. This technology not only improves the health and overall experience of occupants but also reduces energy consumption and carbon emissions. View's products are integrated into a cloud-connected smart building platform, which includes essential infrastructure for power, networking, and communication. The company has successfully implemented its solutions in over 90 million square feet of various building types, including offices, hospitals, airports, educational institutions, hotels, and multifamily residences.

Tarveda Therapeutics is focused on developing innovative cancer therapies specifically for solid tumors. The company specializes in miniature drug conjugates, with its lead candidate, PEN-866, targeting activated Heat Shock Protein 90 (HSP90) to deliver a potent topoisomerase 1 inhibitor, SN38, directly to tumor cells. Additionally, Tarveda is advancing another drug conjugate aimed at treating patients with neuroendocrine tumors and small cell lung cancer that express somatostatin receptor 2 (SSTR2). By leveraging its targeted drug delivery platform, Tarveda Therapeutics aims to improve treatment outcomes for patients with difficult-to-treat cancers while reducing potential side effects. Founded in 2011 and based in Watertown, Massachusetts, the company was previously known as Blend Therapeutics until its rebranding in 2016.

View is a technology company specializing in smart building solutions, particularly through its innovative smart windows. These windows utilize artificial intelligence to automatically adjust to sunlight, enhancing natural light access and providing unobstructed views while also minimizing heat and glare. This technology not only improves the health and overall experience of occupants but also reduces energy consumption and carbon emissions. View's products are integrated into a cloud-connected smart building platform, which includes essential infrastructure for power, networking, and communication. The company has successfully implemented its solutions in over 90 million square feet of various building types, including offices, hospitals, airports, educational institutions, hotels, and multifamily residences.

BIND Therapeutics is a clinical-stage nanomedicine platform company focused on developing targeted and programmable therapeutics known as Accurins. These innovative therapeutics are engineered with specific physical and chemical properties to effectively target particular cells or tissues, allowing for the concentration of therapeutic agents at disease sites. This approach aims to enhance treatment efficacy while reducing adverse effects on healthy tissues. BIND Therapeutics primarily concentrates on oncology, with its lead drug candidate, BIND-014, currently undergoing Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate-resistant prostate cancer. The company also collaborates with biopharmaceutical firms to develop Accurins utilizing therapeutic payloads from their pipelines. Its operations extend to the United States and Russia, focusing on targeting tumors at tissue, cellular, and molecular levels.

Crocus Technology SA specializes in magnetic random access memory products and technologies tailored for the semiconductor and electronic systems industries. The company develops magnetic sensors and embedded memory technology that facilitate efficient sensor data gathering and processing. Its products are designed for diverse applications, including telecommunications, networking, storage, computing, and handheld devices. Crocus Technology's innovative solutions enable fast read and write operations while maintaining a compact footprint, which enhances chip performance and security for devices such as smart cards, mobile phones, and data servers. By focusing on high sensitivity, stable temperature performance, and low power consumption, the company aims to improve productivity for its clients across various sectors.

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary platform utilizes advances in immunobiology and nanotechnology to create targeted immunomodulatory nanoparticles. Selecta's lead product, SEL-212, has successfully completed Phase II clinical trials for chronic refractory gout. Additionally, the company is advancing gene therapy candidates in preclinical development for rare metabolic disorders, including SEL-302 for methylmalonic acidemia and SEL-313 for ornithine transcarbamylase deficiency. Founded in 2007 and headquartered in Watertown, Massachusetts, Selecta Biosciences has established collaborations with various organizations, including Spark Therapeutics and the Massachusetts Institute of Technology, to enhance its research and development capabilities.

SBA Materials, Inc. specializes in the development and commercialization of advanced electronic materials tailored for the semiconductor manufacturing industry, particularly in back-end of line and packaging applications. Founded in 2001 and based in Albuquerque, New Mexico, the company focuses on low-k dielectric materials for interlayer dielectric applications, addressing significant needs in the sector. Its product offerings include uLK22, uLK1X, and various optical films, along with nano-porous and meso-porous materials. These materials can be utilized in diverse forms such as thin films, powders, and fibers, and can be chemically functionalized for applications in electronics, optics, sensors, and catalysts. The company operates from a facility at the Science and Technology Park, which features R&D laboratories and is strategically located near the University of New Mexico and the Sandia National Laboratories Materials Research Center. SBA Materials aims to enhance the performance of electronic devices while reducing power consumption, thereby supporting manufacturers in producing more efficient logic chips.

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary platform utilizes advances in immunobiology and nanotechnology to create targeted immunomodulatory nanoparticles. Selecta's lead product, SEL-212, has successfully completed Phase II clinical trials for chronic refractory gout. Additionally, the company is advancing gene therapy candidates in preclinical development for rare metabolic disorders, including SEL-302 for methylmalonic acidemia and SEL-313 for ornithine transcarbamylase deficiency. Founded in 2007 and headquartered in Watertown, Massachusetts, Selecta Biosciences has established collaborations with various organizations, including Spark Therapeutics and the Massachusetts Institute of Technology, to enhance its research and development capabilities.

Crocus Technology SA specializes in magnetic random access memory products and technologies tailored for the semiconductor and electronic systems industries. The company develops magnetic sensors and embedded memory technology that facilitate efficient sensor data gathering and processing. Its products are designed for diverse applications, including telecommunications, networking, storage, computing, and handheld devices. Crocus Technology's innovative solutions enable fast read and write operations while maintaining a compact footprint, which enhances chip performance and security for devices such as smart cards, mobile phones, and data servers. By focusing on high sensitivity, stable temperature performance, and low power consumption, the company aims to improve productivity for its clients across various sectors.

Xtellus, Inc. specializes in the development of passive optical components designed for agile optical networking systems. The company offers a range of products, including wavelength selective switches, wavelength blockers, edge wavelength selective switches, and reconfigurable optical add/drop multiplexers (ROADM) with integrated power monitoring, as well as multiplexers and demultiplexers. Additionally, Xtellus provides liquid crystal optical processors, enabling efficient management of optical signals in various networking applications. Founded in 2000 and headquartered in Morris Plains, New Jersey, Xtellus maintains manufacturing and development facilities in Israel and South Korea, along with a research and development center in Jerusalem. As of December 2009, Xtellus operates as a subsidiary of Oclaro, Inc.

BIND Therapeutics is a clinical-stage nanomedicine platform company focused on developing targeted and programmable therapeutics known as Accurins. These innovative therapeutics are engineered with specific physical and chemical properties to effectively target particular cells or tissues, allowing for the concentration of therapeutic agents at disease sites. This approach aims to enhance treatment efficacy while reducing adverse effects on healthy tissues. BIND Therapeutics primarily concentrates on oncology, with its lead drug candidate, BIND-014, currently undergoing Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate-resistant prostate cancer. The company also collaborates with biopharmaceutical firms to develop Accurins utilizing therapeutic payloads from their pipelines. Its operations extend to the United States and Russia, focusing on targeting tumors at tissue, cellular, and molecular levels.

HAYA Therapeutics is focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company's innovative approach involves targeting a heart-specific regulator of fibrosis, specifically a long noncoding RNA, to block myocardial fibrosis. This biopharmaceutical therapy aims to improve the efficacy and safety of treatment for heart-related illnesses and other serious health conditions associated with aging, including cancer. By concentrating on tissue and cell-selective genomic medicines, HAYA Therapeutics seeks to provide more precise and effective therapeutic options for patients suffering from these conditions.